delete Therapeutic Goods Amendment Regulations 2003 (No. 4)
An amendment to the Therapeutic Goods Regulations 2003, registered in 2005. Without seeing the specific amendments, this likely relates to changes in the regulatory framework governing the approval, manufacturing, labeling, or distribution of therapeutic goods (medicines, medical devices) in Australia.
Therapeutic goods regulation imposes massive compliance costs on Australian businesses, delaying life-saving treatments for years through bureaucratic approval processes. The regulation creates artificial scarcity, inflating prices of medicines and medical devices while stifling innovation and competition. The compliance burden falls heaviest on small Australian manufacturers and importers, reducing domestic competitiveness. These regulations assume consumers cannot make their own risk assessments, treating adults as children unable to evaluate products with professional medical guidance. The unseen costs include: preventable deaths from delayed access to treatments, reduced R&D investment, and diversion of resources from actual healthcare to paperwork. Private certification, tort law, and market-based quality signals would provide adequate safety without the state-enforced monopoly barriers that impoverish Australians and violate the principle of self-ownership.